When the FDA declared a semaglutide shortage in 2022, pharmacies, telehealth companies and other health care providers could manufacture copycat GLP-1 therapies
Human use is not FDA-approved, but accumulated clinical experience is reassuring: Common and mild Injection site reaction: mild redness, swelling, tenderness - resolves within hours
Peluso at al
At 20 mg/mL, even the maximum dose fits comfortably in a 1.0 mL syringe with room to spare
Este medicamento puede causar efectos secundarios, como nuseas/vmitos, diarrea, estreimiento, dolor abdominal, dispepsia, reacciones en el lugar de la inyeccin, fatiga, reacciones de hipersensibilidad, gases, cada del cabello, ERGE, distensin abdominal, mareos e hipotensin
This causes nausea, reflux, and vomiting